Colliers Securities Thinks Chembio Diagnostics’ Stock is Going to Recover

In a report released today, Kyle Bauser from Colliers Securities reiterated a Buy rating on Chembio Diagnostics (CEMI), with a price target of $8.00. The company’s shares closed last Thursday at $3.52, close to its 52-week low of $3.01.

According to, Bauser is a 4-star analyst with an average return of 16.5% and a 65.2% success rate. Bauser covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Inspire Medical Systems, and Semler Scientific.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Chembio Diagnostics with a $8.00 average price target.

See today’s analyst top recommended stocks >>

Chembio Diagnostics’ market cap is currently $71.04M and has a P/E ratio of -2.60. The company has a Price to Book ratio of 3.91.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Chembio Diagnostics, Inc. develops, manufactures, markets and licenses rapid point-of-care diagnostic tests that detect infectious diseases. Its products include human and veterinary diagnostics. The company was founded in 1985 and is headquartered in Medford, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts